AI Engines For more Details: Perplexity Kagi Labs You
Nasal Decongestion: Xylometazoline works by constricting blood vessels in the nasal passages, reducing swelling and congestion. It provides relief from nasal congestion, allowing for easier breathing and alleviating symptoms such as stuffiness, runny nose, and sinus pressure.
Symptomatic Relief: Xylometazoline can provide temporary relief from symptoms of nasal congestion, including congestion, sinus pressure, and runny or stuffy nose. It helps to open up the nasal passages, making it easier to breathe and reducing discomfort associated with nasal congestion.
Fast Onset of Action: Xylometazoline typically has a rapid onset of action, providing relief from nasal congestion within minutes of application. This quick relief makes it a popular choice for individuals seeking immediate relief from nasal congestion symptoms.
Topical Application: Xylometazoline hydrochloride is usually administered topically as a nasal spray or drops. It is applied directly into the nostrils, where it acts locally to reduce nasal congestion without significant systemic absorption.
Short-Term Use: Xylometazoline is intended for short-term use to relieve acute nasal congestion associated with conditions such as allergies, colds, or sinusitis. Prolonged or excessive use of xylometazoline nasal sprays can lead to rebound congestion, where nasal congestion worsens after discontinuation of the medication.
Precautions: Individuals with certain medical conditions, such as hypertension, cardiovascular disease, diabetes, thyroid disorders, or prostate enlargement, should use xylometazoline with caution and under the guidance of a healthcare professional. It is important to follow the recommended dosage and duration of use to avoid adverse effects.
Adverse Effects: Common side effects of xylometazoline may include temporary stinging or burning sensation in the nose, dryness or irritation of the nasal mucosa, sneezing, and increased nasal discharge. In rare cases, systemic effects such as increased heart rate, elevated blood pressure, headache, dizziness, or insomnia may occur.
Contraindications: Xylometazoline should not be used in individuals who are hypersensitive to the medication or its components. It should also be avoided in certain medical conditions, such as severe hypertension, severe coronary artery disease, narrow-angle glaucoma, and hyperthyroidism.
Drug Interactions: Xylometazoline may interact with certain medications, including monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants, potentially leading to increased blood pressure or adverse cardiovascular effects. It is important to consult a healthcare professional before using xylometazoline in combination with other medications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 0.8 | 0.8 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.6 | 0.4 | 3 |
| Allergies | 1.8 | 0.6 | 2 |
| Allergy to milk products | 0.4 | 1.6 | -3 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 2 | 2 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.1 | 11 |
| Ankylosing spondylitis | 2.5 | 0.6 | 3.17 |
| Anorexia Nervosa | 0.7 | 0.7 | 0 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 1.3 | 0.9 | 0.44 |
| Atherosclerosis | 0.7 | 0.7 | |
| Atrial fibrillation | 1.7 | 1.9 | -0.12 |
| Autism | 2 | 3.5 | -0.75 |
| Autoimmune Disease | 0.9 | 0.3 | 2 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 1.6 | 0.3 | 4.33 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 0.5 | -0.67 |
| Carcinoma | 1.9 | 1 | 0.9 |
| Celiac Disease | 0.7 | 1.9 | -1.71 |
| Cerebral Palsy | 0.9 | 0.3 | 2 |
| Chronic Fatigue Syndrome | 0.9 | 1.9 | -1.11 |
| Chronic Kidney Disease | 1.6 | 0.6 | 1.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
| Chronic Urticaria (Hives) | 0.9 | 0.1 | 8 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 1.1 | |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 1.8 | 0.6 | 2 |
| Constipation | 1.2 | 1.2 | |
| Coronary artery disease | 0.7 | 0.7 | 0 |
| COVID-19 | 2.3 | 1 | 1.3 |
| Crohn's Disease | 3 | 1.6 | 0.88 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 0.6 | 0.17 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 0.7 | 0.3 | 1.33 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 3.3 | 2.5 | 0.32 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.9 | 0.4 | 1.25 |
| Endometriosis | 1.7 | 0.6 | 1.83 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.3 | 1.1 | 0.18 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 1 | 0.6 | 0.67 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 1.1 | 0.91 |
| gallstone disease (gsd) | 1.5 | 0.3 | 4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.3 | 0.33 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 1.3 | 0.9 | 0.44 |
| Gulf War Syndrome | 0.4 | -0.4 | |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1 | 1.2 | -0.2 |
| Heart Failure | 1.6 | 0.3 | 4.33 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.1 | 0.3 | -2 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.8 | 1 | -0.25 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2 | 1.2 | 0.67 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.7 | 0.3 | 4.67 |
| IgA nephropathy (IgAN) | 0.7 | 0.9 | -0.29 |
| Inflammatory Bowel Disease | 2.2 | 2.2 | 0 |
| Insomnia | 0.6 | 0.9 | -0.5 |
| Intelligence | 0.4 | 0.4 | |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.8 | 1.6 | 0.13 |
| ischemic stroke | 1.4 | 0.9 | 0.56 |
| Liver Cirrhosis | 2.5 | 1.2 | 1.08 |
| Long COVID | 2.4 | 1.8 | 0.33 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
| ME/CFS with IBS | 0.6 | -0.6 | |
| ME/CFS without IBS | 1.3 | -1.3 | |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 2.2 | 2.1 | 0.05 |
| Mood Disorders | 3.3 | 2.5 | 0.32 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.6 | 2 | -0.25 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 1.4 | -1.4 | |
| Neuropathy (all types) | 1 | -1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 0.9 | 0.56 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 2.6 | 2 | 0.3 |
| obsessive-compulsive disorder | 2 | 0.6 | 2.33 |
| Osteoarthritis | 1.1 | 0.6 | 0.83 |
| Osteoporosis | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 2 | 2.7 | -0.35 |
| Polycystic ovary syndrome | 2.5 | 0.9 | 1.78 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Primary sclerosing cholangitis | 1.2 | 1.1 | 0.09 |
| Psoriasis | 0.7 | 1.4 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 1 | 1.2 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 2.1 | 1.6 | 0.31 |
| scoliosis | 0.1 | 0.5 | -4 |
| Sjögren syndrome | 1.5 | 1 | 0.5 |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0 | 0 |
| Stress / posttraumatic stress disorder | 1.1 | 1 | 0.1 |
| Systemic Lupus Erythematosus | 2 | 1.2 | 0.67 |
| Tic Disorder | 0.3 | -0.3 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.5 | 1.3 | 0.15 |
| Type 2 Diabetes | 2 | 1.8 | 0.11 |
| Ulcerative colitis | 2.5 | 1.4 | 0.79 |
| Unhealthy Ageing | 1 | 0.7 | 0.43 |
| Vitiligo | 1.4 | 0.7 | 1 |
